The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer

Published:2016-08-03 Issue:1 Volume:5 Page:
ISSN:2193-1801
Container-title:SpringerPlus
language:en
Short-container-title:SpringerPlus

Author:

Yufen Xu,Binbin Song,Wenyu Chen,Jialiang Liu,Xinmei Yang

Funder

Development Center for Medical Science and Technology National Health Commission of the People’s Republic of China

Key Disciplines of Jiaxing (Oncology)

Science and Technology Projects of Jiaxing

Innovation team of Lung Cancer in Early Diagnosis and Comprehensive Treatment

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://link.springer.com/content/pdf/10.1186/s40064-016-2873-2.pdf

Reference60 articles.

1. Ahn M, Tsai C, Yang J, Shepherd F, Satouchi M, Kim D et al (2015) 3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies. Eur J Cancer 51:S625–S626

2. Alimujiang S, Zhang T, Han ZG, Yuan SF, Wang Q, Yu TT et al (2013) Epidermal growth factor receptor tyrosine kinase inhibitor versus placebo as maintenance therapy for advanced non- small-cell lung cancer: a meta-analysis of randomized controlled trials. Asian Pac J Cancer Prev 14(4):2413–2419

3. Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF et al (2006) Novel D761Y and common secondary T790 M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12(21):6494–6501. doi: 10.1158/1078-0432.ccr-06-1570

4. Burotto M, Manasanch EE, Wilkerson J, Fojo T (2015) Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. Oncologist 20(4):400–410. doi: 10.1634/theoncologist.2014-0154

5. Chamberlain MC (2005) Neoplastic meningitis. J Clin Oncol 23(15):3605–3613. doi: 10.1200/jco.2005.01.131

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fate and Efficacy of Engineered Allogeneic Stem Cells Targeting Cell Death and Proliferation Pathways in Primary and Brain Metastatic Lung Cancer;Stem Cells Translational Medicine;2023-06-13

2. Cerebrospinal Fluid Cell-Free DNA-Based Detection of High Level of Genomic Instability Is Associated With Poor Prognosis in NSCLC Patients With Leptomeningeal Metastases;Frontiers in Oncology;2022-04-28

3. Integrin α5 promotes migration and invasion through the FAK/STAT3/AKT signaling pathway in icotinib‑resistant non‑small cell lung cancer cells;Oncology Letters;2021-05-24

4. Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?;Translational Lung Cancer Research;2020-12

5. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study;Journal of Clinical Oncology;2020-02-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3